The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome. METHODS: We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. RESULTS: During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes. CONCLUSIONS: Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“once weekly subcutaneous injection with semaglutide resulted in a marked and sustained weight loss of >15% in patients who are overweight or obese.”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Paulus, W. J., Tschöpe, C., Sanderson, J. E., Rusconi, C., Flachskampf, F. A., Rademakers, F. E., Marino, P. N., Smiseth, O. A., Keulenaer, G. W. D., Leite-Moreira, A. F., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm037 · Cited by 2,646
Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study
Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., Gong, Y., & Liu, P. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051530 · Cited by 1,959
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,001
Zhang, Q., Chen, Y., Liu, Q., & Shan, Q. (2015) · Herz · doi:10.1007/s00059-015-4346-8 · Cited by 18
Yalçın, F., Yalçın, H., Küçukler, N., & Abraham, T. P. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2010.101 · Cited by 18
Pedrotty, D. M., & Jessup, M. L. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.001700 · Cited by 17
Badar, A., Moreno, A. C. P., Hawkins, N. M., Brunton, A. P. T., Jhund, P. S., Wong, C. M., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.221 · Cited by 18
Self-citationDiastolic heart failure: a misNOmer
Heusch, G. (2009) · Basic Research in Cardiology · doi:10.1007/s00395-009-0025-3 · Cited by 18
Heart failure with preserved ejection fraction — coming to terms with an oxymoron
Macdonald, P. S. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03390.x · Cited by 18
Hypertension and Heart Failure with Preserved Ejection Fraction
Lee, C. J., & Park, S. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.002 · Cited by 20
Fuentes-Abolafio, I. J., Escriche-Escuder, A., Bernal-López, M. R., Gómez‐Huelgas, R., Ricci, M., Trinidad‐Fernández, M., Roldán‐Jiménez, C., Arjona-Caballero, J. M., Cuesta‐Vargas, A., & Perez-Belmonte, L. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102692 · Cited by 17
From mid-range to mildly reduced ejection fraction heart failure: A call to treat
Stolfo, D., Fabris, E., Lund, L. H., Savarese, G., & Sinagra, G. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.05.030 · Cited by 17
Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
Talha, K. M., & Butler, J. (2022) · Clinical Cardiology · doi:10.1002/clc.23846 · Cited by 19
Wang, R., Ye, H., Zhao, Y., Wei, J., Wang, Y., Zhang, X., & Wang, L. (2022) · BMC Medicine · doi:10.1186/s12916-022-02682-w · Cited by 20
Hiraiwa, H., Okumura, T., & Murohara, T. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00641-9 · Cited by 19
Update on Heart Failure with Preserved Ejection Fraction
Hummel, S. L., & Kitzman, D. W. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0350-9 · Cited by 17
Site selection for heart failure clinical trials in the USA
Harinstein, M. E., Butler, J., Greene, S. J., Fonarow, G. C., Stockbridge, N., O’Connor, C. M., Pfeffer, M. A., Mehra, M. R., Solomon, S. D., Yancy, C. W., et al. (2015) · Heart Failure Reviews · doi:10.1007/s10741-015-9473-z · Cited by 16
Self-citationAndersen, M. J., Ersbøll, M. K., Bro‐Jeppesen, J., Møller, J. E., Hassager, C., Køber, L., Borlaug, B. A., Goetze, J. P., & Gustafsson, F. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.09.012 · Cited by 17
Li, J., Becher, P. M., Blankenberg, S., & Westermann, D. (2013) · Cardiology Research and Practice · doi:10.1155/2013/130724 · Cited by 17
Lim, S. L., Benson, L., Dahlström, U., Lam, C. S. P., & Lund, L. H. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003534 · Cited by 17
Heart failure with preserved ejection fraction: a nephrologist-directed primer
Afşar, B., Rossignol, P., van Heerebeek, L., Paulus, W. J., Damman, K., Heymans, S. R. B., van Empel, V. P. M., Sag, A. A., Maisel, A., & Kanbay, M. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9619-2 · Cited by 17
Novel Insights and Treatment Strategies for Right Heart Failure
Lin, W., Poh, A.-L., & Tang, W. H. W. (2018) · Current Heart Failure Reports · doi:10.1007/s11897-018-0389-5 · Cited by 17
Schelbert, E. B. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.12.009 · Cited by 17
A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats
Nakajima, Y., Ito, S., Asakura, M., Min, K.-D., Fu, H. Y., Imazu, M., Hitsumoto, T., Takahama, H., Shindo, K., Fukuda, H., et al. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.03.009 · Cited by 17
Reassessing Phase II Heart Failure Clinical Trials
Butler, J., HAMO, C. E., Udelson, J. E., O’Connor, C. M., Sabbah, H. N., Metra, M., Shah, S. J., Kitzman, D. W., Teerlink, J. R., Bernstein, H. S., et al. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003800 · Cited by 17
Self-citationThe E/e’ Ratio—Role in Risk Stratification of Acute Heart Failure with Preserved Ejection Fraction
Zamfirescu, M.-B., Ghilencea, L.-N., Popescu, M. R., Bejan, G. C., Maher, S. M., Popescu, A.-C., & Dorobanţu, M. (2021) · Medicina · doi:10.3390/medicina57040375 · Cited by 18
Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure
Ferreira, J. P., Packer, M., Butler, J., & Zannad, F. M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2457 · Cited by 18
Heart failure with preserved ejection fraction: insights from recent clinical researches
Kim, M., & Park, S. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.104 · Cited by 17
Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure
Casella, G., Struthers, A. D., & Lang, C. C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0403-7 · Cited by 18
Chronic Heart Failure in Older Adults
Ahmed, A. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.02.001 · Cited by 17
Therapeutic approaches to diastolic dysfunction
Janardhanan, R., Desai, A. S., & Solomon, S. D. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0048-z · Cited by 17
Heart failure with preserved ejection fraction: A clinical crisis
Banerjee, P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.170 · Cited by 17
Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes
van Giessen, A., Winter, L. J. M. B.-D., Rutten, F. H., Cramer, M. J., Landman, M. A. J., Liem, A. H., Hoes, A. W., & Koffijberg, H. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0363-z · Cited by 17
Hanff, T. C., Kaye, D. M., Hayward, C., Post, M. C., Málek, F., Hasenfuβ, G., Gustafsson, F., Burkhoff, D., Shah, S. J., Litwin, S. E., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.019 · Cited by 17
The Singapore Heart Failure Risk Score: Prediction of Survival in Southeast Asian Patients
Yap, J. J. L., Chia, S. Y., Lim, F. Y., Allen, J. C., Teo, L. L. Y., Sim, D., Go, Y. Y., Jaufeerally, F. R., Seow, M., Kwok, B. W. K., et al. (2019) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v48n3p86 · Cited by 17
Left-Ventricular Diastolic Dysfunction as a Risk Factor for Dialytic Hypotension
Rostoker, G., Griuncelli, M., Loridon, C., Benmaadi, A., & Illouz, E. (2009) · Cardiology · doi:10.1159/000224776 · Cited by 17
Management of hypertension in chronic heart failure
Manickavasagam, S., Merla, R., Koerner, M. M., Fujise, K., Kunapuli, S., Rosanio, S., & Barbagelata, A. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.8 · Cited by 16
Edelmann, F. (2015) · ESC Heart Failure · doi:10.1002/ehf2.12037 · Cited by 17
Trask-Marino, A. L., Marino, B., Lancefield, T. F., See, E. J., May, C. N., Booth, L. C., Raman, J., & Lankadeva, Y. R. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2024 · Cited by 19
Vaduganathan, M., Claggett, B. L., Chatur, S., Desai, A. S., Jhund, P. S., Vardeny, O., Merkely, B. P., Martínez, F. A., Colet, J. C., Saraiva, J. F. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04037-3 · Cited by 18
Self-citationvan Veldhuisen, D. J., & McMurray, J. J. V. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs194 · Cited by 16
Self-citationAli, D., Callan, N., Ennis, S., Powell, R., McGuire, S., McGregor, G., Weickert, M. O., Miller, M. A., Cappuccio, F. P., & Banerjee, P. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027984 · Cited by 16
Leite, M., Sampaio, F., Saraiva, F. A., Diaz, S. O., Barros, A. S., & Fontes‐Carvalho, R. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14284 · Cited by 14
Chen, X., Kang, Y., Dahlström, U., & Fu, M. L. X. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14358 · Cited by 16
Fazio, S., Mercurio, V., Fazio, V., Ruvolo, A., & Affuso, F. (2024) · Biomedicines · doi:10.3390/biomedicines12040806 · Cited by 17
Causland, F. R. M., Vaduganathan, M., Claggett, B. L., Gori, M., Jhund, P. S., McGrath, M. M., Neuen, B. L., Packer, M., Pfeffer, M. A., Rouleau, J. L., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.022 · Cited by 17
Self-citationA Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine
Liu, L. C. Y., Voors, A. A., Valente, M. A. E., & van der Meer, P. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.12.005 · Cited by 16
Pareek, M., Nielsen, M. L., Gerke, O., Leósdóttir, M., Møller, J. E., Hindersson, P., Sehestedt, T. B., Wachtell, K., Nilsson, P. M., & Olsen, M. H. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.037 · Cited by 16
Cardiology: Pharmacologic Management of Heart Failure with Preserved Ejection Fraction
Huang, D., & Cheng, J. W. M. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p372 · Cited by 16
Recent advances in treatment of heart failure
Kitai, T., & Tang, W. H. W. (2015) · F1000Research · doi:10.12688/f1000research.7022.1 · Cited by 16
Pulmonary hypertension in heart failure with preserved left ventricular ejection fraction
Ohara, T., Ohte, N., & Little, W. C. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32835220b1 · Cited by 16
Liu, S., Guan, Z., Jin, X., Meng, P., Wang, Y., Zheng, X., Jia, D., Ma, C., & Yang, J. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.21956 · Cited by 16
Krittanawong, C., & Kukin, M. L. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0623-1 · Cited by 16
Vaidya, G. N., & Abramov, D. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2018.02.008 · Cited by 16
Indications for β‐Blocker Prescriptions in Heart Failure with Preserved Ejection Fraction
Yum, B., Archambault, A. N., Levitan, E. B., Dharamdasani, T., Kneifati-Hayek, J. Z., Hanlon, J. T., Diaz, I. M., Maurer, M. S., Lachs, M. S., Safford, M. M., et al. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15977 · Cited by 16
Shear, F. E. (2019) · Europe PMC (PubMed Central) · Cited by 16
Shuai, W., Kong, B., Yang, H., Fu, H. Q., & Huang, H. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12620 · Cited by 16
Fukuta, H., Goto, T., Wakami, K., Kamiya, T., & Ohte, N. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09969-1 · Cited by 16
Can mechanical circulatory support be an effective treatment for HFpEF patients?
Gude, E., & Fiane, A. E. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10154-1 · Cited by 16
Zeng, J., Zhou, Y., & Zhu, Y. (2021) · Current Molecular Medicine · doi:10.2174/1566524021666211129111202 · Cited by 16
Yuyun, M. F., Kinlay, S., Singh, J. P., & Joseph, J. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14248 · Cited by 15
Excess Pressure Integral Predicts Long-Term All-Cause Mortality in Stable Heart Failure Patients
Wang, W., Sung, S., Wang, J., Wu, C., Lin, L., Lee, J.-C., Cheng, H., & Chen, C.-H. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw133 · Cited by 16
The Three-Decade Long Journey in Heart Failure Drug Development
Lewis, K. S., Butler, J., Bauersachs, J. K., & Sandner, P. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_101 · Cited by 16
Sex and Gender-Related Issues in Heart Failure
Romiti, G. F., Recchia, F., Zito, A., Visioli, G., Basili, S., & Raparelli, V. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.08.005 · Cited by 17
Barrios, V., Escobar, C., de la Sierra, Á., Llisterri, J. L., & Alsina, D. G.-S. (2010) · Blood Pressure · doi:10.3109/08037051.2010.488051 · Cited by 16
Otto Kamp, B., Metra, M., Keulenaer, G. W. D., Pieske, B. M., Conraads, V. M., Zamorano, J. L., Huysse, L., Vardas, P. E., Böhm, M., & Cas, L. D. (2009) · Clinical Research in Cardiology · doi:10.1007/s00392-009-0098-x · Cited by 16
Why we need tobacco sales data for good tobacco control
GARTNER, C. E., Chapman, S. F., Hall, W., & Wakefield, M. A. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03389.x · Cited by 16
Heart Failure With a Normal Ejection Fraction (HFNEF): Embracing Complexity
Maurer, M. S. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.04.004 · Cited by 16
Understanding Results of Trials in Heart Failure With Preserved Ejection Fraction
Kitzman, D. W. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.013 · Cited by 16
Vlasopoulou, K., Synetos, A. G., Ktenopoulos, N., Katsaros, O., Koliastasis, L., Apostolos, A., Drakopoulou, M. I., Toutouzas, K. P., & Tsioufis, K. P. (2025) · Medical Sciences · doi:10.3390/medsci13030204 · Cited by 19
Redefining Heart Failure Phenotypes Based on Ejection Fraction
Campbell, R. T., Petrie, M. C., & McMurray, J. J. V. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1325 · Cited by 15
Self-citationGorter, T. M., van Veldhuisen, D. J., Mulder, B. A., Arita, V. A., van Empel, V. P. M., Manintveld, O. C., Tieleman, R. G., Maass, A. H., Vernooy, K., Gelder, I. C. V., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113682 · Cited by 16
NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure
Habeeb, W. A., Tash, A. A., Elasfar, A., Almasood, A. S., Bakhsh, A., Elshaer, F., Ayoubi, F. A., Alghalaini, K., Alqaseer, M., Alhussein, M., et al. (2023) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1334 · Cited by 16
Doiron, J. E., Xia, H., Yu, X., Nevins, A., LaPenna, K. B., Sharp, T. E., Goodchild, T. T., Allerton, T. D., Elgazzaz, M., Lazartigues, E. D., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16493 · Cited by 15
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 15
Evolving role of myocardial fibrosis in heart failure with preserved ejection fraction
Malik, M. K., Kinno, M., Liebo, M., Yu, M. D., & Syed, M. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1573346 · Cited by 15
Heart failure with preserved ejection fraction
Alsamara, M., & Alharethi, R. A. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.911086 · Cited by 14
Frontiers of Therapy for Patients With Heart Failure
Liu, S. S., Monti, J., Kargbo, H. M., Athar, M. W., & Parakh, K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.033 · Cited by 16
Smith, D. T., Farzaneh‐Far, R., Ali, S., Na, B., Whooley, M. A., & Schiller, N. B. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.677 · Cited by 15
Sakamoto, K., Hosokawa, K., Saku, K., Sakamoto, T., Tobushi, T., Oga, Y., Kishi, T., Ide, T., & Sunagawa, K. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00610.2015 · Cited by 15
Sakamoto, M., Asakura, M., Nakano, A., Kanzaki, H., Sugano, Y., Amaki, M., Ohara, T., Hasegawa, T., Anzai, T., & Kitakaze, M. (2015) · International journal of gerontology · doi:10.1016/j.ijge.2015.06.003 · Cited by 15
Pharmacological interventions for heart failure in people with chronic kidney disease
Ravani, P., Quinn, R. R., & Strippoli, G. F. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466 · Cited by 16
McGuinty, C., Leong, D., Weiss, A. J., MacIver, J., Kaya, E., Hurlburt, L., Billia, F., Ross, H. J., & Wentlandt, K. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.12.357 · Cited by 17
Liu, J., Liu, Y., Lin, H., Zhou, B., Yu, H., Li, L., Wang, C., Li, X., Li, P., Liu, J., et al. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104325 · Cited by 15
Garoffolo, G., & Pesce, M. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100036 · Cited by 15
Management of Pulmonary Hypertension in Left Heart Disease
Macera, F., & Vachiéry, J. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/rkqn5397 · Cited by 18
Yalçın, F., Yalçın, H., Küçukler, N., Arslan, S., Akkuş, O., Kurtul, A., & Abraham, M. R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010075 · Cited by 15
Ageev, F. T., & Ovchinnikov, A. G. (2022) · Kardiologiia · doi:10.18087/cardio.2022.7.n2058 · Cited by 16
Mancusi, C., Lembo, M., Manzi, M. V., Basile, C., Fucile, I., & Morisco, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185377 · Cited by 15
Lin, Y., Cai, Z., Yuan, J., Liu, H., Pang, X., Chen, Q., Tang, X., Geng, Q., & Dong, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01679-2 · Cited by 16
Basile, C., Paolillo, S., Gargiulo, P., Marzano, F., Asile, G., Parlati, A. L. M., Chirico, A., Nardi, E., Buonocore, D., Colella, A., et al. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001411 · Cited by 17
Heart Failure with Preserved Ejection Fraction
Hummel, S. L. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5198-2_16 · Cited by 15
Comparative assessment of angiotensin receptor blockers in different clinical settings
Verdecchia (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s7263 · Cited by 15
New Insights in the Diagnosis and Treatment of Heart Failure
Agnetti, G., Piepoli, M. F., Siniscalchi, G., & Nicolini, F. (2015) · BioMed Research International · doi:10.1155/2015/265260 · Cited by 15
Chan, M. C. Y., & Tsuyuki, R. T. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32835dd0e9 · Cited by 15
Shuai, X., Meng, Y., Lu, Y.-X., Su, G., Tao, X., Han, J., Xu, S.-D., & Luo, P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.05.011 · Cited by 15
What the General Practitioner Needs to Know About Their Chronic Heart Failure Patientt
Rutten, F. H., & Gallagher, J. (2016) · Cardiac failure review · doi:10.15420/cfr.2016:18:1 · Cited by 15
Diagnosis and Management of Heart Failure in Older Adults
Panjrath, G. S., & Ahmed, A. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.02.002 · Cited by 15
What’s new in heart failure therapy 2018?†
Westphal, J. G., Bekfani, T., & Schulze, P. C. (2018) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivy282 · Cited by 15
Possibility of a New Therapeutic Strategy for Left Ventricular Dysfunction in Type 2 Diabetes
Sakamoto, M., Matsutani, D., & Kayama, Y. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3584w · Cited by 15
Tillman, F., Kim, J., Makhlouf, T. K., & Osae, L. (2019) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944719840192 · Cited by 18
Aimo, A., Senni, M., Barison, A., Panichella, G., Passino, C., Bayés‐Genís, A., & Emdin, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10228-8 · Cited by 16
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3440 · Cited by 19
Metadata
- Authors
- Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., & Ptaszynska, A.
- Affiliations
- San Francisco VA Medical Center (US)
- Georgetown University (US)
- University of Glasgow (GB)
- Hamilton Health Sciences (CA)
- Medical University of South Carolina (US)
- University of Wisconsin–Madison (US)
- Bristol-Myers Squibb (United States) (US)
- Sanofi (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-04
- Volume
- 359
- Issue
- 23
- Pages
- 2456-2467
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068519950
- Cited by
- 1,960
- References
- 37
- Citations by year
- 2026: 61 · 2025: 72 · 2024: 92 · 2023: 94 · 2022: 128 · 2021: 120 · 2020: 123 · 2019: 118 · 2018: 117 · 2017: 138 · 2016: 105 · 2015: 127 · 2014: 119 · 2013: 122 · 2012: 109
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- irbesartan, heart failure with preserved ejection fraction, angiotensin receptor blockers, cardiovascular mortality, cardiovascular hospitalization, heart failure hospitalization, quality of life, elderly patients
- MeSH terms
- Irbesartan, Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiovascular Diseases, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Quality of Life, Stroke Volume, Tetrazoles, Proportional Hazards Models, Treatment Failure, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
